Predictive value of exhaled nitric oxide in healthy infants for asthma at school age
- Jakob Usemann1,2,
- Oliver Fuchs1,2,3,4,
- Pinelopi Anagnostopoulou2,
- Insa Korten1,2,
- Olga Gorlanova1,
- Martin Röösli5,6,
- Philipp Latzin1,2 and
- Urs Frey1⇑
- 1University Children's Hospital Basel (UKBB), Basel, Switzerland
- 2Division of Respiratory Medicine, Dept of Paediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
- 3Dr von Hauner Children's Hospital, Ludwig-Maximilians-University, Munich, Germany
- 4Comprehensive Pneumology Centre Munich (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany
- 5Swiss Tropical and Public Health Institute Basel, Basel, Switzerland
- 6University of Basel, Basel, Switzerland
- Urs Frey, University Children's Hospital Basel, Basel, Switzerland, Spitalstrasse 33, 4056 Basel, Switzerland. E-mail: urs.frey{at}ukbb.ch
Abstract
FeNO in newborns before exposure to environmental factors is not associated with school-age asthma development http://ow.ly/ShQQ300xiN2
To the Editor:
Exhaled nitric oxide fraction (FeNO) is a noninvasive biomarker that is elevated in subjects with asthma and allergic diseases [1]. Nitric oxide (NO) is produced by three NO synthase (NOS) enzymes: neuronal, endothelial and inducible (iNOS), all present in the human lung [2]. The increase of FeNO in asthmatic patients has mainly been attributed to an activation of iNOS, mediated through proinflammatory cytokines in the airways [3].
Early monitoring of airway inflammation assessed by elevated FeNO provides information on asthma evolvement and helps to identify subjects at risk. Few studies have investigated the association between FeNO during early childhood and asthma at school age. In pre-school children with recurrent respiratory symptoms, those with higher FeNO were at an increased risk of asthma at 6 years [4]. In a selected cohort of infants with eczema, increased FeNO prior to any wheezing episodes was associated with an increased risk of asthma at 5 years [5]. Notably, in these studies, FeNO was measured in high-risk children who were already exposed to environmental factors known to modify FeNO levels [6–8].
The value of FeNO after birth to predict later symptoms before relevant exposure to environmental factors has been prospectively investigated in only two studies [9, 10]. Latzin et al. [9] reported that infants born to atopic mothers had increased FeNO prior to respiratory symptoms and that this association was enhanced in mothers who smoked. In infants born to asthmatic mothers, Chawes et al. [10] showed that increased FeNO was associated with recurrent wheezing episodes during the first year of life but not thereafter.
Taken together, while there is cumulative evidence that elevated FeNO in high-risk children after a possible impact by environmental exposures is associated with later asthma [4, 5], it is unknown if FeNO after birth, prior to a possible influence by post-natal environmental exposures and first respiratory symptoms, is associated with asthma. Given that environmental factors are known to induce NOS activity and modify FeNO [6, 7, 11, 12], we hypothesised that FeNO measured after birth, and before relevant exposure to these factors, is not associated with asthma at school age.
The aim of this prospective cohort study was to investigate if FeNO levels after birth in unselected newborns are associated with asthma or atopy at school age. This prospective birth cohort study comprised of unselected, healthy, term-born infants recruited in the region of Bern, Switzerland [13]. At 5 weeks of age, FeNO was measured from multiple breaths during natural sleep, as previously described [9, 14], with a rapid response chemiluminescence analyser (CLD 77; EcoMedics, Duernten, Switzerland) (analysis software: WBreath version 3.28.0.0; ndd, Zurich, Switzerland).
At 6 years of age, asthma was assessed by study physicians with questions adapted from the ISAAC (International Study of Asthma and Allergies in Childhood) questionnaire [15], defined as a history of wheezing within the 12 months prior to follow-up. Study physicians assessed atopy, defined as allergic asthma, allergic rhinitis, atopic dermatitis or positive skin-prick test (SPT). An SPT including seven common allergens was determined to be positive in the case of hives bigger than positive control, histamine, with any of the tested allergens [13]. We assessed risk factors for asthma or atopy of the child: parental asthma was defined as self-reported or doctor-diagnosed asthma; parental atopic disease was defined as allergic asthma, hay fever or eczema by history.
The Governmental Ethics Committee of the Canton of Bern, Switzerland approved the study and informed, written consent was obtained at enrolment.
Logistic regression was used for analysis of an association between FeNO at birth and asthma, atopy and positive SPT at school age. Adjustment for confounders (e.g. parental asthma and atopy) and nonconfounding factors (minute ventilation, which is known to modify FeNO [16]) was done. Linear regression was used for the analysis of an association between parental variables and FeNO at birth. Data are presented as odds ratios or difference in FeNO (in parts per billion) with 95% confidence intervals. Data were analysed with STATA 13 (STATA Corporation, College Station, TX, USA). Patient characteristics for those with and without follow-up were compared using Mann–Whitney U-test and Chi-squared test.
We measured FeNO in 278 infants with 44 (16%) being excluded for technical reasons, resulting in 234 subjects. Of those 26 (12%) were lost to follow-up, resulting in 208 final study participants. Demographics, exposure to risk factors and FeNO levels did not differ between subjects followed up and those lost to follow-up (data not shown). For the entire group, neither maternal atopy nor maternal smoking was associated with postnatal FeNO. Smoking during pregnancy was only associated with decreased FeNO levels in infants of nonatopic mothers (−2.91 ppb, 95% CI −5.76– −0.048 ppb). These findings were similar to previously published data [16], although the fraction of smoking mothers was lower in this study (9% versus 13% [16]). At 5 weeks of age, mean FeNO was 13.9 ppb (range 1.8–32.9 ppb). Parents of 43 (20%) children had asthma and those of 126 (61%) were atopic; 19 (10%) mothers smoked during pregnancy. Among 6-year-olds (age range 5–7 years), 31 (15%) had asthma with 13 (6%) allergic asthma cases, and none of the children used corticosteroids. There were 62 (30%) atopics and in 164, an SPT was completed with 26 (19%) being positive.
FeNO at birth was not associated with asthma, atopy or positive SPT at school age. Per 1-ppb increase in FeNO, the simple and adjusted odds ratios for asthma were 0.99 (95% CI 0.92–1.07) and 0.97 (95% CI 0.89–1.06); for atopy, 0.99 (95% CI 0.94–1.05) and 0.99 (95% CI 0.94–1.06); and for positive SPT, 0.95 (95% CI 0.88–1.03) and 0.95 (95% CI 0.87–1.03), respectively (table 1).
Our study is the first to investigate the association between FeNO at birth and asthma at school age in unselected infants. It was previously shown that the association of elevated FeNO after birth with respiratory symptoms is restricted to infancy [10]. In this study, we found supporting evidence for this finding, since FeNO after birth was not associated with diagnosis of school age asthma.
Based on this finding, and on previous studies in selected high-risk populations, we propose two different models of FeNO metabolism in early infancy (figure 1). In model 1, elevated FeNO is an expression of an intrinsic mechanism, determined by pre- and early postnatal risk factors. In this model, FeNO levels during infancy would then not be altered by environmental factors, and FeNO measured at birth could serve as a predictor for later asthma and atopy. In model 2, environmental factors (e.g. infections or air pollution) are needed to induce iNOS [6, 7, 11], which then results in elevated FeNO. In this hypothesis, we would expect no association between FeNO at birth (measured before environmental exposures) and school-age outcomes. FeNO may then only serve as a phenotype-specific biomarker in infants after the first activation of the environmentally or genetically induced iNOS. We speculate that the second, rather than the first, model better explains NO metabolism after birth, since studies measuring FeNO after environmental exposures found an association between FeNO and asthma development, while our study, measuring FeNO before environmental exposures, did not find any association.
Measurements were performed using a face mask, which is the only available technique for measuring FeNO in infants at this time. This introduces the possibility that NO from the upper airways contributes to the overall FeNO measured. However, we believe this potential contribution is unlikely due to the fact that the nasal sinuses of infants are not developed.
Asthma prediction with FeNO might further be hampered by the physiological variability of FeNO per se, by an intersubject variability of up to 50% [18], and influenced by different measurement techniques. In school-aged children, comparison of FeNO measured from single versus multiple breaths resulted in higher FeNO values using the latter technique [19]. Multiple-breath FeNO measurement technique is, at this time, the only one available for infants. The present study is limited by the low number of asthmatics (n=31) and the questionnaire-based assessment for diagnosis, which could lead to possible misclassification. In general, the cohort reflects the epidemiological situation in Switzerland, with a low prevalence of mild-to-moderate asthmatics. Coincidentally, however, in our study sample, only mild intermittent asthmatics (without corticosteroid use in the last 12 months) were included, but this study was conducted in a prospective, unselected cohort, representing the general population. In contrast to previous studies in high-risk populations, we measured FeNO at a single point in time after birth, excluding possible age- or time-dependent effects on FeNO.
The interpretation of FeNO, its predictive value and its modifiers are age dependent [4, 5, 7, 9–11]. Postnatal FeNO metabolism seems to be modified by various environmental factors. On a cellular level, maternal tobacco smoke modified NOS activity in the fetal vascular bed in newborns [12]. Consistent with this observation, postnatal FeNO is modified by prenatal tobacco smoke exposure in offspring [16, 17], interestingly enough, in an interaction with maternal atopy [16]. In contrast to the pre- and early postnatal situation, infancy and preschool age seems to be critical for further gene–environment interactions through exposures other than smoking and maternal atopy and their impact upon NO metabolism [4, 5].
In summary, we show that postnatal FeNO measured in unselected healthy newborns is not associated with asthma diagnosis at school age. We speculate that NO metabolism may play a role in the pathophysiology of childhood asthma and atopy only after exposure to environmental factors at preschool age. To confirm that environmental exposures indeed modify NOS expression during infancy, frequent longitudinal assessment of FeNO levels and NOS expression would be necessary. Our findings should encourage further research on factors impacting upon NO metabolism during infancy that can serve as targets for new preventive strategies on childhood asthma development.
Acknowledgments
The authors would like to thank all study participants for participating in the study, along with our lung function technicians Gisela Wirz and Sharon Schmid, and our study nurses Christine Becher, Monika Graf, Barbara Hofer, Sandra Lüscher and Linda Beul-Béguin (all Division of Respiratory Medicine, Dept of Paediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland) for their support. We thank Karine Landgren Hugentobler (UKBB, Basel, Switzerland) for helping with English style.
Footnotes
Support statement: This study was supported by the Swiss National Science Foundation grant 320030_163311 to U. Frey and P. Latzin. Funding information for this article has been deposited with the Open Funder Registry.
Conflict of interest: None declared.
- Received March 1, 2016.
- Accepted May 12, 2016.
- Copyright ©ERS 2016